- Home
- WLDN vs PHVS Comparison
WLDN vs PHVS Comparison
Compare WLDN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLDN
- PHVS
- Stock Information
- Founded
- WLDN 1964
- PHVS 2015
- Country
- WLDN United States
- PHVS Switzerland
- Employees
- WLDN N/A
- PHVS N/A
- Industry
- WLDN Military/Government/Technical
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- WLDN Consumer Discretionary
- PHVS Health Care
- Exchange
- WLDN Nasdaq
- PHVS Nasdaq
- Market Cap
- WLDN 1.6B
- PHVS 1.6B
- IPO Year
- WLDN 2006
- PHVS 2021
- Fundamental
- Price
- WLDN $95.36
- PHVS $22.71
- Analyst Decision
- WLDN Strong Buy
- PHVS Buy
- Analyst Count
- WLDN 3
- PHVS 4
- Target Price
- WLDN $114.33
- PHVS $33.00
- AVG Volume (30 Days)
- WLDN 365.6K
- PHVS 222.4K
- Earning Date
- WLDN 10-30-2025
- PHVS 11-12-2025
- Dividend Yield
- WLDN N/A
- PHVS N/A
- EPS Growth
- WLDN 94.22
- PHVS N/A
- EPS
- WLDN 2.39
- PHVS N/A
- Revenue
- WLDN $628,172,000.00
- PHVS N/A
- Revenue This Year
- WLDN N/A
- PHVS N/A
- Revenue Next Year
- WLDN $9.00
- PHVS N/A
- P/E Ratio
- WLDN $38.42
- PHVS N/A
- Revenue Growth
- WLDN 13.82
- PHVS N/A
- 52 Week Low
- WLDN $30.43
- PHVS $11.51
- 52 Week High
- WLDN $121.00
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- WLDN 40.89
- PHVS 45.84
- Support Level
- WLDN $90.62
- PHVS $22.07
- Resistance Level
- WLDN $94.14
- PHVS $24.01
- Average True Range (ATR)
- WLDN 3.90
- PHVS 1.17
- MACD
- WLDN -0.88
- PHVS -0.30
- Stochastic Oscillator
- WLDN 11.29
- PHVS 20.18
About WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.